Journal: Vaccines

Article Title: Advancements in Cancer Immunotherapies

doi: 10.3390/vaccines11010059

Figure Lengend Snippet: Summary of small drugs inhibitors.

Article Snippet: Multitarget TKI (VEGFRs, FGFRs, PDGFRα, RET, and KIT) , Lenvatinib mesylate (Lenvima) , Thyroid cancer (2015) , FDA approved , [ ] .

Techniques: Mutagenesis

Journal: Pharmaceutics

Article Title: Targeted Glioma Therapy—Clinical Trials and Future Directions

doi: 10.3390/pharmaceutics16010100

Figure Lengend Snippet: Selected clinical trials investigating multikinase inhibitors in glioma (combined recognition moiety and a payload).

Article Snippet: NCT00948389 (July 2009–August 2012) , PDGFRβ, EPHA2, BCR-Abl, c-Kit and SRC multitarget TKI , Combined with lomustine (N = 26, PFS = 1.35 months, OS = 6.4 months [ ]) .

Techniques: Clinical Proteomics

Journal: Pharmaceutics

Article Title: Targeted Glioma Therapy—Clinical Trials and Future Directions

doi: 10.3390/pharmaceutics16010100

Figure Lengend Snippet: Selected clinical trials investigating multikinase inhibitors in glioma (combined recognition moiety and a payload).

Article Snippet: NCT01100177 (April 2010–March 2013) , PDGFRα/β, c-Kit, VEGFR1/2/3, FLT3 and RET multitarget TKI , Monotherapy prior, during and after RT (N = 12, PFS = 7.7 weeks, OS = 12.8 weeks [ ]) .

Techniques: Clinical Proteomics

Journal: Cold Spring Harbor Molecular Case Studies

Article Title: Pazopanib elicits remarkable response in metastatic porocarcinoma: a functional precision medicine approach

doi: 10.1101/mcs.a006308

Figure Lengend Snippet: Ex vivo drug testing results of 18 different drugs on fresh biopsies of the patient's lung metastases demonstrating the efficacy of pazopanib. ( A ) Box and whiskers plot comparing IC 50 data with Genomics of Drug Sensitivity in Cancer (GDSC) data set. Drugs used in our single-drug testing assay are listed on the y -axis, and corresponding log-transformed IC 50 values are listed on the x -axis. The box and whiskers plots represent the median, interquartile range, and 95% confidence intervals from the GDSC data set. Mean IC 50 value from GDSC is denoted by “+,” whereas the patient IC 50 value is represented by the magenta dot. ( B ) Dose–response curves for pazopanib and irinotecan, the top two drugs, with the largest leftward deviation of IC 50 of the patient's tumor sample from the mean IC 50 values from the GDSC data set. ( C ) Dose–response curves of the remaining drugs in order of ascending IC 50 values. All dose–response curves are represented as means (SD) of two technical replicates.

Article Snippet: Based on the lack of standard systemic treatment options in PC, the lack of actionable targets on CGP of the tumor sample, and ex vivo drug testing results, the patient was started on the oral multitarget TKI pazopanib 800 mg in January 2022.

Techniques: Ex Vivo, Transformation Assay

Journal: Cold Spring Harbor Molecular Case Studies

Article Title: Pazopanib elicits remarkable response in metastatic porocarcinoma: a functional precision medicine approach

doi: 10.1101/mcs.a006308

Figure Lengend Snippet: Computed tomography (CT) images of the chest before and after pazopanib treatment, showing remarkable radiological outcomes. ( A ) CT images of the chest before pazopanib treatment in January 2022. ( B ) CT images of the chest after 2 mo of pazopanib treatment in March 2022. Several bilateral pulmonary lesions demonstrating a decrease in size and cavitation are shown. Cavitation suggests tumor liquefaction and necrosis, consistent with known patterns of radiological response to pazopanib .

Article Snippet: Based on the lack of standard systemic treatment options in PC, the lack of actionable targets on CGP of the tumor sample, and ex vivo drug testing results, the patient was started on the oral multitarget TKI pazopanib 800 mg in January 2022.

Techniques: Computed Tomography

Journal: ESMO Open

Article Title: Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?

doi: 10.1016/j.esmoop.2022.100638

Figure Lengend Snippet: Most prevalent genomic alterations in PDAC. Genes are grouped by signaling pathway or molecular process. Prevalence is reported as % of total PDAC patients. These statistics are adapted from 2 sources: A) an international cohort of 3594 PDAC patients undergoing targeted genomic profiling, ¹⁵ and B) a targeted genomic screening of 640 patients treated for pancreatic cancer, of which 591 had an histologically confirmed pancreatic adenocarcinoma. ²¹

Article Snippet: , Vemurafenib Sorafenib , BRAF Multitarget TKI (VEGFR, RAF, PDGFR...) , No , M, L ≥3, KRAS G12D mutation , II , Recruiting NCT05068752.

Techniques: Homologous Recombination, Control

Journal: ESMO Open

Article Title: Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?

doi: 10.1016/j.esmoop.2022.100638

Figure Lengend Snippet: Selected ongoing clinical trials evaluating targeted therapies as monotherapy in metastatic PDAC

Article Snippet: , Vemurafenib Sorafenib , BRAF Multitarget TKI (VEGFR, RAF, PDGFR...) , No , M, L ≥3, KRAS G12D mutation , II , Recruiting NCT05068752.

Techniques: Clinical Proteomics, Mutagenesis, Expressing